This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Conway, M. A. Articles by Rajagopalan, B. Search for Related Content PubMed PubMed Citation Articles by Conway, M. A. Articles by Rajagopalan, B. Pubmed/NCBI databases Compound via MeSH Substance via MeSH

(Circulation. 1998;97:1716-1723.)
© 1998 American Heart Association, Inc.

Clinical Investigation and Reports

Mitral Regurgitation

Impaired Systolic Function, Eccentric Hypertrophy, and Increased Severity Are Linked to Lower Phosphocreatine/ATP Ratios in Humans

Michael A. Conway, MD, MSc, MRCP; Paul A. Bottomley, PhD; Ronald Ouwerkerk, PhD; George K. Radda, DPhil, FRS; ; Bheeshma Rajagopalan, DPhil, FRCP

From the MRC Biochemical and Clinical Magnetic Resonance Spectroscopy Unit, John Radcliffe Hospital, Oxford, UK (M.A.C., G.K.R., B.R.); the Department of Radiology, Johns Hopkins University, Baltimore, Md (P.A.B.); and University Hospital, Utrecht, Holland (R.O.).

Background—A number of phosphorus (³¹P) magnetic resonance spectroscopy (MRS) studies link alterations of high-energy phosphate metabolism in valvular disease and cardiomyopathy to the clinical severity of heart failure. However, correlations between MRS and indexes of ventricular dysfunction are inconclusive to date. We examined whether changes in ³¹P MRS are associated with the impaired contractility, which predisposes to chronic congestive heart failure in patients with mitral regurgitation.

Methods and Results—Thirteen normal control subjects and 22 patients with echocardiographically characterized chronic mitral regurgitation were studied by ³¹P MRS. The apical phosphocreatine-to-ATP ratio (PCr/ATP) was lower in severe disease (P<.02) and those on therapy (n=13, 1.29±0.29, P<.01) in contrast to control subjects (n=13, 1.61±0.3). Compared to those with mild mitral regurgitation, patients with more severe incompetence had lower mean myocardial PCr/ATP ratios (mild, n=6, 1.73 [0.17], P<.05 and P<.01; moderate, n=5, 1.49 [0.18], P<.05; and severe, n=11, 1.29 [0.32], P<.01). PCr/ATP in those referred for mitral valve replacement was lower (n=8, 1.17±0.23) although not significantly decreased compared with the ratio among subjects on medical therapy alone (n=5, 1.48±0.29). PCr/ATP correlated with the end-systolic diameter (r²=.7, P<.001), end-diastolic diameter (r²=.32, P<.05), left ventricular wall thickness (r²=.38, P<.01), left atrial dimension (r²=.36, P<.05), and derived measurements such as the percent fractional shortening (r²=.5, P<.01), and left ventricular mass/body surface area (r²=.5, P<.001) but not with wall stress.

Conclusions—These results demonstrate that abnormalities of PCr/ATP in mitral regurgitation are related to disease severity as measured by dimensional indexes of left ventricular dilatation. They suggest that impaired high-energy phosphate metabolism is a marker of hypertrophy and heart failure.

Key Words: mitral valve • spectroscopy • heart failure • echocardiography • myocardium

This article has been cited by other articles:

				L. E. Hudsmith and S. Neubauer Magnetic resonance spectroscopy in myocardial disease. J. Am. Coll. Cardiol. Img., January 1, 2009; 2(1): 87 - 96. [Abstract] [Full Text] [PDF]

				S. G. Haworth The cell and molecular biology of right ventricular dysfunction in pulmonary hypertension Eur. Heart J. Suppl., December 1, 2007; 9(suppl_H): H10 - H16. [Abstract] [Full Text] [PDF]

				S. Gizurarson, M. Lorentzon, T. Ramunddal, F. Waagstein, L. Bergfeldt, and E. Omerovic Effects of complete heart block on myocardial function, morphology, and energy metabolism in the rat Europace, June 1, 2007; 9(6): 411 - 416. [Abstract] [Full Text] [PDF]

				S. Nemoto, P. Razeghi, M. Ishiyama, G. De Freitas, H. Taegtmeyer, and B. A. Carabello PPAR-{gamma} agonist rosiglitazone ameliorates ventricular dysfunction in experimental chronic mitral regurgitation Am J Physiol Heart Circ Physiol, January 1, 2005; 288(1): H77 - H82. [Abstract] [Full Text] [PDF]

				M. Beer, T. Seyfarth, J.o. Sandstede, W. Landschutz, C. Lipke, H. Kostler, M. von Kienlin, K. Harre, D. Hahn, and S. Neubauer Absolute concentrations of high-energy phosphate metabolites in normal, hypertrophied, and failing human myocardium measured noninvasively with 31P-SLOOP magnetic resonance spectroscopy J. Am. Coll. Cardiol., October 2, 2002; 40(7): 1267 - 1274. [Abstract] [Full Text] [PDF]

				R. Lodi, B. Rajagopalan, A. M Blamire, J.M. Cooper, C. H Davies, J. L Bradley, P. Styles, and A. H.V Schapira Cardiac energetics are abnormal in Friedreich ataxia patients in the absence of cardiac dysfunction and hypertrophy: An in vivo 31P magnetic resonance spectroscopy study Cardiovasc Res, October 1, 2001; 52(1): 111 - 119. [Abstract] [Full Text] [PDF]

				E. Braunwald Congestive heart failure: a half century perspective Eur. Heart J., May 2, 2001; 22(10): 825 - 836. [PDF]

				J. G. Crilley, E. A. Boehm, B. Rajagopalan, A. M. Blamire, P. Styles, F. Muntoni, D. Hilton-Jones, and K. Clarke Magnetic resonance spectroscopy evidence of abnormal cardiac energetics in Xp21 muscular dystrophy J. Am. Coll. Cardiol., November 15, 2000; 36(6): 1953 - 1958. [Abstract] [Full Text] [PDF]

				M. Wyss and R. Kaddurah-Daouk Creatine and Creatinine Metabolism Physiol Rev, July 1, 2000; 80(3): 1107 - 1213. [Abstract] [Full Text] [PDF]

				E. Bollano, E. Omerovic, M. Bohlooly-Y, V. Kujacic, B. Madhu, J. Tornell, O. Isaksson, B. Soussi, W. Schulze, M. L. X. Fu, et al. Impairment of Cardiac Function and Bioenergetics in Adult Transgenic Mice Overexpressing the Bovine Growth Hormone Gene Endocrinology, June 1, 2000; 141(6): 2229 - 2235. [Abstract] [Full Text] [PDF]